Satellite Symposia 2014

Satellite Symposia are non-commercial scientific sessions supported by industry to complement the official program and to extend the educational experience of meeting attendees. They may include one or a number of speakers and may cover one or several topics, and will contain objectivity in the presentation. Satellite Symposia are not part of the official ICAAC 2014 scientific sessions as planned by the ICAAC Program Committee.

 

Saturday, September 6

Back to the Patient: Re-Focusing Antimicrobial Stewardship
Supported by Cubist Pharmaceuticals

Cubist-Logo

7:00 a.m.–9:00 a.m.
Walter E. Washington Convention Center
Room 206

Speakers:

7:30 a.m.–8:05 a.m.
Measuring the Impact of Antimicrobial Stewardship Programs: A Patient-Centered Approach
Craig A. Martin, PharmD, BCPS
Clinical Associate Professor, Department of Pharmacy Practice and Science,
University of Kentucky College of Pharmacy, Lexington, KY

This session will educate the clinician on how to identify patient-centered outcomes to measure the performance of an ASP, including the feasibility of capturing such measures and consideration of the changing healthcare landscape in the era of healthcare reform.  

8:05 a.m.–8:40 a.m.
Using Quasi-Experimental Study Design to Evaluate Antimicrobial Stewardship Programs
Anthony D. Harris, MD, MPH
Professor of Medicine, University of Maryland School of Medicine,
Baltimore, MD

This session will inform the clinician on various types of quasi-experimental studies, including the advantages and disadvantages of each type and consideration of variability in resource availability.

 

Establishing Best Practices for the Diagnosis and Management of Invasive Fungal Infections (IFIs)
Supported by Astellas, IMMY, MiraVista Diagnostics & MiraBella Technologies, and Viracor-IBT Laboratories

AstellasCommittedDiseases 4C    Immy
MVD-logo Viracor-IBT Laboratories logo


7:00 p.m.–9:30 p.m.
Marriott Marquis
Liberty Ballroom Salons IJKL

Complimentary CME/CE dinner symposium.

CME/CE Credit provided by AKH Inc., Advancing Knowledge in Healthcare.  This activity has been approved for AMA PRA Category 1 Credit™.  This activity is eligible for ACPE, ANCC, and AANP credit; see final CE activity announcement for specific details.  Full accreditation information available www.akhcme.com/ICAAC

Questions/Comments: (904) 683-8843


Speakers:

For activity accreditation and faculty details please visit www.akhcme.com/ICAAC

Kieren Marr MD
Professor of Medicine and Oncology, Director, Transplant and Oncology Infectious Diseases Program, Johns Hopkins University School of Medicine, Baltimore MD  

Keith M Olsen, PharmD, FCCP, FCCM
Professor of Pharmacy, Chair, Department of Pharmacy Practice, University of Nebraska Medical Center, Omaha, NE

George Thompson, MD
Assistant Professor of Clinical Medicine, Lawrence J. Ellison Ambulatory Care Center, Infectious Diseases Clinic, Sacramento CA

Program Overview
The live interactive symposium will be a Case-Based Approach with faculty Q&A.  Objective include 1) assess the role of laboratory assays and techniques for diagnosing and guiding infection control and treatment decisions in patients with invasive fungal infections (IFIs) including invasive aspergillosis , invasive candidiasis , mucormycosis, and rare molds; 2) Differentiate new and emerging therapeutic options for the prophylaxis, empirical treatment, pre-emptive and targeted treatment of invasive fungal infections (IFIs) including invasive aspergillosis and invasive candidiasis; and 3) Apply appropriate antifungal therapy based on evidence-based guideline recommendations, antifungal  resistance patterns, and patient specific factors.

 

Antifungal Stewardship: Rapid Diagnostics to Address the Resistance Crisis
Supported by T2 Biosystems

T2-Biosystems-Logo

7:00 p.m.–9:00 p.m.
Marriott Marquis
University of DC & Catholic University

Moderator:

Michael Pfaller, MD
Chief Medical Officer, T2 Biosystems; Professor Emeritus, University of Iowa College of Medicine and College of Public Health

Speakers:

Peter Pappas, MD
William E. Dismukes Professor of Medicine; Principal Investigator, Mycoses Study Group; Division of Infectious Diseases; University of Alabama at Birmingham

Cornelius Clancy, MD
Associate Professor of Medicine, Director, Mycology Program, University of Pittsburgh, Pittsburgh, PA

Kevin W. Garey, PharmD, MS, FASHP
Chair, Department of Clinical Sciences & Administration; Professor of Pharmacy Practice, University of Houston, Houston, TX

Eleftherios Mylonakis, MD, PhD, FIDSA
Chief, Division of Infectious Diseases, Dean's Professor of Medical Science, Professor of Medicine, Rhode Island Hospital and The Miriam Hospital, Providence, RI

Program Overview:

The U.S. Centers for Disease Control and Prevention, or the CDC, recently called antifungal resistance ‘‘one of our most serious health threats” in the United States. Join a panel of leading experts that will discuss best practices in the management of patients at risk for Candida infections and the methods that can be deployed to decrease the growing threat of resistant pathogens. The discussion will include how the application of rapid diagnostics may deliver significant improvements in patient outcomes while reducing hospital costs, and review case studies on effective antifungal stewardship strategies.


Dinner will be served. Please register online at http://info.t2biosystems.com/ICAACSymposium

 

Sunday, September 7

Clinical Decision Making in Mycology: Working Through Difficult Scenarios
Supported by Merck; Gilead Sciences Europe, Ltd; T2 Biosystems; and MiraVista Diagnostics
Jointly provided by UNMC CCE; Terranova Medica, LLC;  and the MSG-ERC
 

MERCK    Gilead-Logo---High-Def
T2-Biosystems-Logo MVD-logo

5:30 p.m.–7:45 p.m.
Marriott Marquis
Liberty Ballroom Salons IJKL

Speakers:

Introduction and Review of Existing and Emerging Diagnostics and Therapeutics
Peter G. Pappas, MD, FACP
William E. Dismukes Professor of Medicine; Principal Investigator, Mycoses Study Group; Division of Infectious Diseases; University of Alabama at Birmingham


Hematologic Malignancy/HSCT Patient
Oliver A. Cornely, MD, FACP, FIDSA
Professor of Internal Medicine, Clinical Trials Centre Cologne, University of Cologne, Germany

At-Risk ICU Patient
David R. Andes, MD
Professor of Medicine and Medical Microbiology and Immunology; Head, Division of Infectious Diseases; University of Wisconsin School of Medicine and Public Health

Program Overview:
Despite advances in IFI management, unmet needs remain for these challenging conditions.  Many factors affect IFI outcomes—some are modifiable, while others are not. Do we know which decisions under clinician control are most critical for achieving optimal outcomes in IFI management? What kind of difference do newer diagnostics and therapeutics make or do we anticipate they will make? Can clinicians recognize barriers to effective treatment and overcome them to improve patient outcomes?  

Clinical Decision Making in Mycology: Working through Difficult Scenarios is an MSG-ERC CME symposium designed to address these questions. After an introduction and review of commercially available and emerging therapeutic and diagnostic options, the activity will turn to an in-depth exploration of two cases—a hematologic malignancy and an intensive care unit case—that illustrate key decision points affecting potential outcomes across the disease spectrum. By using a branching, decision-tree approach that follows the cases out to potential logical conclusions, the activity challenges learners to evaluate their own practice patterns in an effort to overcome barriers and achieve better outcomes for IFIs.

 

Debating the Challenges and Opportunities in Managing Serious Bacterial Infections
Supported by Cubist Pharmaceuticals
Jointly provided by Vemco MedEd and Center for Independent Healthcare Education

Cubist-Logo 


5:30 p.m.–8:00 p.m.
Marriott Marquis
Marquis Ballroom Salons 1-4

Please register at:  http://www.vemcomeded.com/livemeetings.asp

Physicians:
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint providership of Center for Independent Healthcare Education (Center) and Vemco MedEd. Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Center designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacists :
acpeCenter for Independent Healthcare Education is accredited by the Accreditation Council for Pharmacy Education as a provider for continuing pharmacy education. Center has assigned 2.0 contact hours (0.2 CEUs) of continuing pharmacy education credits for participating in this activity.

ACPE UAN: 0473-999-14-005-L01-P
Activity type: Knowledge-based


Speakers:

George G. Zhanel, PharmD, PhD, FCCP
Professor, Department of Medical Microbiology and Infectious Diseases, Faculty of Medicine, University of Manitoba, Director, Canadian Antimicrobial Resistance Alliance (CARA), Winnipeg, Canada

Thomas M. File, Jr., MD, MS, MACP, FIDSA, FCCP
Chair, Infectious Disease Division, Summa Health System, Akron, OH, Professor, Internal Medicine, Master Teacher; Chair, Infectious Disease Section, Northeast Ohio Medical University, Rootstown, OH

Erik R. Dubberke, MD, MSPH
Associate Professor of Medicine, Director, Section of Transplant Infectious Diseases, Washington University School of Medicine, St. Louis, MO

Richard H. Drew, PharmD, MS, BCPS, FCCP
Professor, Campbell University College of Pharmacy and Health Sciences, Associate Professor of Medicine (Infectious Diseases, Duke University School of Medicine, Durham, NC

Program Agenda:

5:30 p.m.
Registration and Dinner

6:00 p.m.
Call-to-Action Introduction

6:10 p.m.
Round 1: MRSA and VRE Infections
Challenges–Richard H. Drew, PharmD
Opportunities–Thomas M. File, Jr., MD

Round 2: ESBL-producing and Carbapenem-Resistant Enterobacteriaceae
Challenges–George G. Zhanel, PharmD, PhD
Opportunities–Richard H. Drew, PharmD

Round 3: Pseudomonas aeruginosa
Challenges–Thomas M. File, Jr., MD
Opportunities–Erik R. Dubberke, MD

Round 4: Clostridium difficile
Challenges–Erik R. Dubberke, MD
Opportunities–George G. Zhanel, PharmD, PhD

7:40 p.m.
Open Forum: Q&A


Program Overview:

The pandemic of multidrug-resistant (MDR) bacteria and their continuing spread is well recognized and considered a global health crisis. In addition to the rising prevalence of MDR pathogens, a growing at-risk patient population has compounded the burden caused by these infections. In particular, infections caused by MRSA, vancomycin-resistant enterococci, Pseudomonas aeruginosa, ESBL-producing and carbapenem-resistant Enterobacteriaceae, and C. difficile continue to present challenges when utilizing current antimicrobials.

Addressing the MDR crisis requires a multifaceted approach, including having a thorough understanding of resistance mechanisms, local epidemiology, rapid diagnostics, and infection control. When an MDR infection is suspected, clinicians must consider patient-, pathogen-, and drug-related factors when selecting an optimal regimen. Newer and emerging agents can offer effective options to address these difficult infections, though their use must be done in an appropriate manner. Clinicians depend on ID specialists for guidance when managing MDR infections and, thus, they must be skilled and competent in the latest research and evidence-based strategies.

Through a debate format, this activity explores the spectrum of available and emerging agents for the treatment of MDR infections and the ways in which clinicians can apply evidence-based treatment approaches in order to reduce the morbidity and mortality of these infections.

 

Should Integrase Inhibitors Be Your First Choice When Starting HIV Therapy? Expert Faculty Debate the Evidence
Supported by ViiV Healthcare

ViiV-Healthcare-Logo

5:30 p.m.–6:00 p.m. Registration and Dinner
6:00 p.m.–7:30 p.m. Symposium

Marriott Marquis
Marquis Ballroom Salon 5


Speakers:

Introduction
Joseph J. Eron, Jr., MD (Program Chair)
Professor of Medicine and Epidemiology, University of North Carolina School of Medicine, Director, AIDS Clinical Trials Unit, University of North Carolina, Chapel Hill, North Carolina


Didactic Presentation: Current Evidence on Integrase Inhibitors in First-Line Therapy

Daniel R. Kuritzkes, MD
Chief, Division of Infectious Diseases, Brigham and Women's Hospital, Professor of Medicine
Harvard Medical School, Boston, Massachusetts


Panel Discussion: Are Integrase Inhibitors the New Gold Standard for First-Line Antiretroviral Therapy?

Eric S. Daar, MD
Chief, Division of HIV Medicine, Harbor-UCLA Medical Center, Professor of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California

Joseph J. Eron, Jr., MD
Professor of Medicine and Epidemiology, University of North Carolina School of Medicine Director, AIDS Clinical Trials University, University of North Carolina, Chapel Hill, North Carolina

Sally Hodder, MD
Professor of Medicine, Rutgers, New Jersey Medical School, Newark, New Jersey

Daniel R. Kuritzkes, MD
Chief, Division of Infectious Diseases, Brigham and Women's Hospital, Professor of Medicine
Harvard Medical School, Boston, Massachusetts

Kathleen E. Squires, MD
Professor of Medicine, Director, Division of Infectious Diseases, Jefferson Medical College
Thomas Jefferson University, Philadelphia, Pennsylvania


Concluding Remarks

Joseph J. Eron, Jr., MD
Professor of Medicine and Epidemiology, University of North Carolina School of Medicine
Director, AIDS Clinical Trials Unit, University of North Carolina, Chapel Hill, North Carolina


Program Overview:
An accumulating body of evidence has demonstrated that integrase inhibitor-based regimens are at least noninferior—and, in several comparative studies, superior—to other regimens currently recommended for first-line antiretroviral therapy. These data raise an important clinical question: Should integrase inhibitor-based regimens now be considered the preferred option for first-line therapy? And if so, what are the advantages and disadvantages that differentiate the available integrase inhibitor-based regimens?

This symposium will use a combination of didactic presentations and case-based discussion to evaluate the merits of integrase inhibitor-based first-line therapy compared with the other guideline-endorsed first-line regimens.  

 

Monday, September 8

World Sepsis Day Roundtable–A Discussion of Significant Challenges and Innovations in the Treatment and Diagnosis of Sepsis
Supported by BD
Hosted by Global Sepsis Alliance

BDlogo 4c-Converted

Please join us for this exciting live discussion. (PACE credits will be offered.)

11:00 a.m.–1:00 p.m.
Walter E. Washington Convention Center
Room 206


Moderator:

Dr. Tom van der Poll
Academic Medical Center, Amsterdam

Speakers:

The Burden of Sepsis
Dr. Phillip Dellinger
Cooper Health System, New Jersey

The Role of Diagnostics in the Treatment of Sepsis
Dr. Rich Rothman
Johns Hopkins Hospital, Maryland

The Role of Biomarkers in the Treatment of Sepsis
Dr. Steven Opal
Brown University, Rhode Island

Program Overview
:
Sepsis causes more deaths per year than prostate cancer, breast cancer and HIV/AIDS combined.  Additionally, inpatient septicemia is the single most expensive condition treated in US hospitals.  To help raise awareness of sepsis in advance of World Sepsis Day on September 13, this Global Sepsis Alliance-hosted, BD-sponsored satellite symposium will take a closer look at some of the current issues surrounding sepsis.  

This symposium will bring together world-renown experts in the field of sepsis diagnosis and treatment.  The roundtable format of this symposium will enable a deep exploration of these topics.

 

Clinical and Economic Value of Rapid Diagnosis in the Critically Ill Population
Supported by Abbott

Abbott-logo-Converted

11:00 a.m.–1:00 p.m.
Walter E. Washington Convention Center
Room 209 A


Speakers:

11:00 a.m.–11:05 a.m.
Welcome and Introductory Comments
Chair/Moderator: Franklin R. Cockerill, MD
Mayo Clinic, Rochester, MN, USA

11:05 a.m.–11:25 a.m.
Improvements in BSI Diagnostic Accuracy by Testing Larger Blood Volumes
Richard Rothman, MD
Johns Hopkins University, Baltimore, MD, USA

11:30 a.m.–11:55 a.m.
Salvage Microbiology: When All Else Fails, Is Molecular Diagnostics Your Only Option?
Robert A. Bonomo, MD
Chief, Medical Service, Louis Stokes Cleveland VA Hospital; Vice Chair, Veterans Affair, Medicine, University Hospital Case Medical Center, Cleveland, OH, USA

12:00 p.m.–12:30 p.m.
RADICAL–A Multi-Center Study Demonstrating Benefits of Rapid Diagnostics Using PCR/ESI-MS
Jean-Louis Vincent, MD
Erasme University Hospital, Université Libre de Bruxelles, Brussels, Belgium, BE

12:30 p.m.–12:50 p.m.
Economic Case for Rapid Diagnosis of Blood Stream Infection Based on RADICAL Data
Robert Bilkovski, MD
Medical and Scientific Affairs, Abbott Molecular, Des Plaines, IL, USA

12:50 p.m.–1:00 p.m.
Concluding Remarks
Franklin R. Cockerill, MD
Mayo Clinic, Rochester, MN, USA

Program Overview:
This will be a scientific session focusing on the recent advances in molecular technologies for the diagnosis of pathogens in critically ill patients, with a particular emphasis on the direct detection of bacteremia/candidemia from blood, without the need for culture. The session will also feature a description of a recently concluded European research study titled RADICAL, which focused on critically ill patient population. A perspective on the clinical and economic value of early and rapid diagnosis will be presented.